Biodesix announced today that Humana, Medical Mutual of Ohio and PreferredOne health plans have established reimbursement coverage of the VeriStrat® test, Biodesix’ proteomic blood test for patients with non-small cell lung cancer (NSCLC). VeriStrat has received positive coverage decisions from Humana, Medical Mutual of Ohio, and PreferredOne and as a result of these coverage changes, an additional 11.5 million Americans now have insurance coverage for VeriStrat.
VeriStrat results provide physicians with prognostic and predictive information to inform treatment of advanced NSCLC, and can facilitate patient-physician conversations about prognosis, life expectancy, and treatment recommendations. The test is clinically proven for use in patients with advanced NSCLC and has been recommended as such in the standard of care guidelines since late 2014. VeriStrat is often used by physicians as part of the Biodesix Lung Reflex™ testing strategy, which combines genomic mutation testing and proteomic testing to provide more complete information on tumor mutation status as well as the patient’s immune response to the tumor.
Based on published clinical data, Humana, Medical Mutual of Ohio and PreferredOne independently determined and published policy stating that VeriStrat can be considered medically necessary for patients with advanced NSCLC.
VeriStrat and Biodesix are registered trademarks of Biodesix, Inc. All other trademarks referenced herein are the property of their respective owners.
Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat® and VeriStrat® tests that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005966/en/Business Wire
Last updated on: 31/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.